HIV Research meeting in conjunction

HIV Research meeting in conjunction with the 18th conference on retroviruses and opportunistic infections (CROI 2011)

Hilton Boston Back Bay, 40 Dalton Street, Boston, USA.
Organized by the World Health Organization and CREATE on behalf of the TB/HIV Working Group of the Stop TB Partnership

TB is the commonest presenting illness and remains a leading cause of death among people living with HIV. Prevention, diagnosis and treatment of both drug-susceptible and drug-resistant TB in people living with HIV are very challenging in resource limited settings which carry the brunt of the problem. There are also numerous unmet research needs that are essential to improve the quality of care for people living with HIV and TB.

WHO in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) and the TB/HIV Working Group of the Stop TB Partnership have been organizing CROI affiliated HIV/TB research meetings since 2007. The popularity, influence and depth of these meetings have been increasing over the years and have been very instrumental in guiding the development of global policy and research agenda.

The 2011 HIV/TB Research meeting will focus on two issues: the use of Xpert MTB/RIF for the rapid diagnosis of HIV-associated TB, and issues and uncertainties around the mouse model for TB drug development. The meeting will share new data from ongoing studies and discuss potential implementation, discuss controversial issues and identify critical research questions.

This CROI affiliated meeting will be held on Sunday February 27, 2011 between 11:30-13:30 in Boston, USA in one of the hotels nearby the Conference centre and venue will be confirmed in due course. Light lunch will be served during the meeting.

Participants: HIV researchers, HIV implementers and public health policy makers.

The meeting will only by invitation and will be on first come first serve basis. If you are interested to participate please send your interest to tbhiv@who.int at your earliest convenience but not later than February 15, 2011.